Short answer
PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial and operational results announced for quarter ended June 30, 2026.
PULSE BIOSCIENCES, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial and operational results announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive results
- Disclosure not deemed filed under Exchange Act Section 18, limiting liability and incorporation implications
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $434,000, while controlled commercial launch keeps near-term sales limited
- GAAP net loss widened to $24.7 million from $19.2 million, driven by heavier clinical and compensation spending
- Cash $101.6 million after $46.8 million ATM proceeds, with an additional $10.7 million raised after quarter-end
- NANOPULSE-AF surpassed 82 evaluable patients, with enrollment target increased by 19 to 164
- Key catalysts include early Q4 2026 catheter enrollment completion and potential CE Mark approvals by mid-2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PULSE BIOSCIENCES, INC. 8-K filings
Get the next PLSE 8-K as it lands
Follow PLSE for push alerts, or ask the research agent what this filing means.